SITC 2021 | The future of monotherapies in melanoma

Omid Hamid • 12 Nov 2021

Melanoma Skin Cancer

Immuno-Oncology

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, shares his thoughts on the future of monotherapies in melanoma. This interview took place during the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting in Washington, D.C.

Advances in utilizing neoadjuvant immunotherapy in melanoma

Omid Hamid • 29 Nov 2022

What does the future hold for LAG-3 as a novel target in melanoma?

Omid Hamid • 29 Nov 2022

The potential impact of lifileucel on the treatment landscape of melanoma

Omid Hamid • 17 Apr 2023

mRNA-4157, a novel mRNA vaccine, with pembrolizumab in melanoma

Omid Hamid • 18 Apr 2023

Related Videos

Clinical trial updates on patient responses with triplet therapy

Jeffrey Weber • 4 Jan 2019

Grant McArthur on the 3 positive melanoma trials presented at the ESMO 2017 Congress

Grant McArthur • 11 Sep 2017

ASCO 2016 melanoma highlights: immunotherapy developments and further data on checkpoint inhibitors

James Larkin • 26 Aug 2016

Combination targeted adjuvant therapy doubles relapse-free survival in stage III melanoma

Axel Hauschild • 11 Sep 2017